Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 9 of 9 for “"nivolumab"”.
-
Papel de los anticuerpos monoclonales en el tratamiento del cáncer de riñón tratados por Urólogos
… de puntos de control inmunológico, como nivolumab, ha supuesto un cambio relevante en el tratamiento del carcinoma de células renales metastásico. Sin embargo, existe un vacío de evidencia en práctica clínica real sobre su manejo dentro del ámbito de la Urología, donde tradicionalmente el …
-
Novel Immunotherapy Agents in Oncology: Generalizability of Trial Results and Drivers of Clinical Utilization
… disease. Novel immunotherapy agents such as nivolumab and pembrolizumab have become an essential, albeit extremely expensive, component of oncology care since their first approvals in melanoma in 2014 and lung cancer in 2015. However, little is known about differences between immunotherapy …
-
An Affinity Threshold for Maximum Efficacy in Anti-PD-1 Cancer Immunotherapy
… widely-used FDA-approved anti-PD-1 antibodies, nivolumab and pembrolizumab have similar single digit nanomolar equilibrium binding constants (KD). Anti-PD-1 antibodies with higher and lower affinity than nivolumab or pembrolizumab are entering the clinic and show varied pre-clinical efficacy. …
-
Ανοσοθεραπεία στο καρκίνο κεφαλής και τραχήλου: μία συστηματική ανασκόπηση / Immunotherapy in head and neck cancer : a systematic review
… σημείων ελέγχου, όπως το Pembrolizumab και το Nivolumab, οι οποίοι έχουν ενταχθεί στη θεραπευτική στρατηγική του υποτροπιάζοντος ή μεταστατικού καρκίνου κεφαλής και τραχήλου, παρουσιάζοντας βελτίωση στη συνολική επιβίωση και σε ορισμένες περιπτώσεις πιο ευνοϊκό προφίλ τοξικότητας. Σκοπός της …
-
Single-cell Functional Profiling of Lymphocytes for Cancer Immunotherapy
… and an immune checkpoint inhibitor (nivolumab, programmed cell death protein 1/PD-1 inhibitor). Sixty-four patient-derived T cells from peripheral blood or bone marrow (site of disease), which were collected before the initiation of the therapy (baseline, T0) and after the first round …
-
Assessing Tumor Mutation Burden and Correlation With Anti-PD-1/L1 Therapy Benefit and Prognosis
… (N=55,962) if they had received pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab, or cemiplimab, and non-ICI therapies, respectively, during the course of treatment for individual cancer types. Patients treated with chemo-immunotherapy combination regimens were included in the ICI …
-
Defining the relationship between the gut microbiome and response to combination immune checkpoint blockade across cancer types
… (CICB), namely ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) therapy, with a uniform clinical schedule. Using a genome-resolved metagenomics and supervised machine learning approach, I demonstrate that sub-species (strain) level gut microbial quantifications can reliably predict response …
-
Immune checkpoints in oral carcinogenesis
… were incubated with different ICIs, anti-PD-1, nivolumab or the IDO1 inhibitor, epacadostat. Study IV revealed that each subpopulation of lymphocytes responded differently to ICI therapy with the release of specific cytokines. The IDO1 inhibitor significantly increased the migration of CD4+ T …